Analysis Mereo’s Clinical Kaleidoscope: All Eyes On Etigilimab (Rating Upgrade)September 22, 2023 Klaus Vedfelt/DigitalVision via Getty Images At a Glance Mereo BioPharma (NASDAQ:MREO) finds itself at a pivotal crossroads, both clinically and…
